The California-based entities plan to offer new Medicare Advantage (MA) products in select counties by this fall.

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Several court cases have been filed against the Trump administration over disruptions touching health care, including funding ...

Despite significant advancements in spinal muscular atrophy (SMA) management, unmet needs persist, especially for patients ...

Experts discuss how to evaluate and communicate the return on investment for continuous glucose monitoring (CGM) coverage to ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of ...

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, ...

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential ...

As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, ...

A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative ...

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at ...